GO:0051169 nuclear transport: Mechanism, Genes, Functions

Nuclear transport (GO:0051169) is the biological process that governs the directed movement of macromolecules into, out of, and within the nucleus. This process is fundamental to eukaryotic life because it maintains the distinct compositions of the nucleoplasm and cytoplasm, allowing transcription and translation to be spatially and temporally separated. The nuclear envelope separates these compartments, and all exchange occurs through nuclear pore complexes (NPCs), large protein channels embedded in the envelope. Nuclear transport receptors (NTRs) recognize specific signals on cargo proteins and mediate their translocation through NPCs, a process that is tightly regulated and energy-dependent. Researchers study nuclear transport because it controls the localization of transcription factors, cell cycle regulators, and signaling molecules, thereby influencing gene expression, cell proliferation, and differentiation. Defects in nuclear transport are increasingly implicated in human diseases, including cancer, neurodegenerative disorders, and viral infections. For example, the mechanical environment can trigger YAP nuclear entry by regulating transport across nuclear pores, linking nuclear transport to mechanotransduction. Moreover, thermal stress has been shown to impact nuclear transport pathways, highlighting the sensitivity of this process to environmental cues. Understanding the molecular mechanisms, key genes, and regulatory networks of nuclear transport is essential for developing targeted therapies and for interpreting genomic and proteomic data. This article provides a comprehensive overview of nuclear transport, its components, and the experimental approaches used to study it, with a focus on CRISPR-based models for functional validation.

According to the Gene Ontology, nuclear transport (GO:0051169) is defined as the directed movement of substances into, out of, or within the nucleus. This encompasses the import of proteins and RNAs from the cytoplasm into the nucleus, the export of molecules from the nucleus to the cytoplasm, and the movement of components within the nuclear compartment. The process is mediated by nuclear transport receptors that recognize cargo and facilitate passage through nuclear pore complexes, often using the Ran GTPase gradient for directionality.

Nuclear transport is essential for eukaryotic cell function because it controls the access of transcription factors, signaling molecules, and RNA-processing machinery to the nucleus, thereby regulating gene expression, cell cycle progression, and development. Dysregulation of nuclear transport is associated with a growing list of human diseases, including cancer, neurodegeneration, and viral pathogenesis, making it a critical area of biomedical research.

The following genes encode core components of the nuclear transport machinery, including nuclear pore complex proteins, nuclear transport receptors, and regulators of the Ran GTPase cycle.

Nuclear transport is regulated at multiple levels. The Ran GTPase gradient provides the primary directionality, but additional layers of regulation include post-translational modifications of cargo and transport receptors, such as phosphorylation, which can alter cargo binding or NPC interaction. Mechanical forces have been shown to regulate YAP nuclear entry by modulating transport across nuclear pores, linking nuclear transport to mechanotransduction. Thermal stress can also impact nuclear transport efficiency, affecting the localization of stress-responsive proteins. Furthermore, the expression levels of nucleoporins and transport receptors are dynamically regulated during cell cycle, differentiation, and in response to signaling pathways, allowing cells to adapt nucleocytoplasmic trafficking to changing needs.

Altered nuclear transport is a hallmark of many cancers. Mutations and chromosomal translocations involving nucleoporins, such as NUP98 and NUP214, are found in leukemias and other malignancies. Overexpression of exportin-1 (XPO1/CRM1) is common in solid tumors and correlates with poor prognosis, leading to the development of XPO1 inhibitors as anticancer drugs. Nuclear transport also regulates the localization of tumor suppressors (e.g., p53, FOXO) and oncogenes (e.g., beta-catenin, NF-kB), and disrupting their transport can promote tumorigenesis.

Defects in nuclear transport are increasingly linked to neurodegenerative diseases. In tauopathies, such as Alzheimer's disease, impaired nuclear transport of Tau and other proteins contributes to neuronal dysfunction. Nuclear transport proteins, including nucleoporins and importins, have been shown to suppress Tau neurodegeneration in model systems, suggesting that enhancing nuclear transport could be therapeutic. Additionally, mutations in nucleoporins are associated with hereditary spastic paraplegia and other neurological disorders.

Many viruses exploit nuclear transport pathways to deliver their genomes into the nucleus and to export viral mRNAs. For example, HIV-1 and influenza virus rely on nuclear import and export machinery for replication. Understanding these interactions has informed antiviral drug development, and nuclear transport inhibitors are being explored as broad-spectrum antivirals.

Fluorescence microscopy, including live-cell imaging and FRAP (fluorescence recovery after photobleaching), is widely used to study nuclear transport dynamics. GFP-tagged cargo proteins and fluorescently labeled nucleoporins allow real-time visualization of import and export in single cells. Super-resolution microscopy can resolve NPC structure and cargo transit.

Nuclear-cytoplasmic fractionation followed by mass spectrometry enables the identification of proteins whose localization changes upon perturbations. Proximity labeling techniques, such as BioID and APEX, can map the interactome of nuclear transport receptors and nucleoporins in living cells. In vitro transport assays using permeabilized cells and recombinant proteins reconstitute the Ran gradient and measure transport kinetics.

CRISPR-Cas9 knockout screens have been used to identify genes required for nuclear transport and to uncover synthetic lethal interactions with transport inhibitors. RNA interference (RNAi) screens and haploid genetic screens have also contributed to the discovery of nuclear transport regulators. These screens can be coupled with reporters that read out nuclear localization of fluorescent cargo.

X-ray crystallography and cryo-electron microscopy have provided high-resolution structures of nucleoporins and their complexes with nuclear transport receptors, revealing the molecular basis of selective gating. NMR spectroscopy has been used to study the dynamics of FG-repeat nucleoporins.

Researchers studying nuclear transport-related genes often need to determine whether a candidate gene is causally involved in a specific transport pathway or disease phenotype. This requires precise genetic models that can knockout, mutate, tag, or overexpress the gene of interest in relevant cell types. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate such functional studies.

Nuclear transport (GO:0051169) is a fundamental biological process that controls the exchange of molecules between the nucleus and cytoplasm, thereby regulating gene expression, cell cycle, and development. Its dysfunction is linked to a wide range of human diseases, including cancer and neurodegeneration. Advances in CRISPR-based genome editing and screening technologies are enabling researchers to dissect the causal roles of nuclear transport components with unprecedented precision. EDITGENE's comprehensive services support these efforts by providing custom knockout, knock-in, point mutation, and overexpression models, as well as CRISPR library screening and bioinformatics analysis.